Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 11:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: T-20 Clear all

Conditions: HIV Infections
Interventions: Enfuvirtide T/20/Ro 29,9800, HIV-1 Infusion Inhibitor; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Enfuvirtide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years and older
Enrollment: 525 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 34
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 27 more

Conditions: HIV Infections
Interventions: Enfuvirtide, Efavirenz, lamivudine, and tenofovir; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 70 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infection
Interventions: T-20; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 1 Diabetes
Interventions: Bolus timing and dosing; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 7 Years to 21 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: HIV Infections
Interventions: Tetanus toxoid, Hepatitis A Vaccine (Inactivated); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 24 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 25
States / cities: Birmingham, Alabama • Alhambra, California • Long Beach, California + 18 more

Conditions: HIV Infections
Interventions: Enfuvirtide, Amdoxovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 8
States / cities: Denver, Colorado • Miami, Florida • Boston, Massachusetts + 2 more

Conditions: HIV Infections
Interventions: Enfuvirtide, Valproic acid; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HER2-positive Breast Cancer
Interventions: Doxorubicin, cyclophosphamide, paclitaxel, docetaxel, Trastuzumab, Pertuzumab; Drug
Lead sponsor: Western Regional Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Goodyear, Arizona

Conditions: HIV Infections
Interventions: Enfuvirtide, Ritonavir, Abacavir sulfate, Amprenavir, Efavirenz; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 20
States / cities: Beverly Hills, California • Los Angeles, California • Palm Springs, California + 14 more

Conditions: HIV Infections
Interventions: Enfuvirtide; Drug
Lead sponsor: Trimeris; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 7 more

Conditions: HIV Infections
Interventions: Enfuvirtide; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 12 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 24
States / cities: La Jolla, California • Long Beach, California • Los Angeles, California + 16 more

Conditions: HIV Infections
Interventions: Interruption of enfuvirtide, enfuvirtide interrupton; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: Enfuvirtide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 3 Years to 16 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 7
States / cities: Los Angeles, California • Gainesville, Florida • New York, New York + 2 more

Conditions: HIV Infections
Interventions: Emtricitabine, Enfuvirtide, Ritonavir, Saquinavir, Tenofovir disoproxil fumarate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 6
States / cities: Aurora, Colorado • Boston, Massachusetts • St Louis, Missouri + 3 more

Conditions: HIV Infections
Interventions: Enfuvirtide-intensified HAART; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Fuzeon (Enfuvirtide) Early Access Program for Patients With HIV-1 Infection

T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance to Each of the Three Classes of Approved Anti-HIV Drugs

A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy

HIV Maintenance Therapy With T-20 During HAART Interruption

Timing of Pre-meal Insulin Versus Accurate Carbohydrate Counting in Youth With Type 1 Diabetes

The Effects of Anti-HIV Therapy on the Immune Systems of Children and Young Adults Infected With HIV

Adding New Drugs for HIV Infected Patients Failing Current Therapy

Study of Valproic Acid to Treat HIV Infected Adults

Fasting on Newly Diagnosed Breast Cancer

A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults

A Study of T-20 in HIV-Positive Adults

Study of a New Anti-HIV Drug, T-20, in HIV-Infected Children

Pilot Study Evaluating Interruption of Enfuvirtide (Fuzeon, T20) in Patients With Enfuvirtide Resistance

T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and Adolescents

Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults

Treatment Intensification for HIV Infected Patients With Multi-Drug Resistant Virus